ArmaGen is a privately held, clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders.

The company is advancing innovative therapies for the treatment of currently unaddressed neurological complications of lysosomal storage disorders (LSDs), as well as neurodegenerative diseases such as Alzheimer’s and Parkinson’s.

Because most medications are unable to penetrate the blood-brain barrier (BBB), there is a clear unmet medical need to treat neurological complications of many diseases, including LSDs and neurodegenerative diseases. ArmaGen’s pipeline is based on decades of scientific leadership in engineering therapies to non-invasively penetrate the BBB, resulting in a unique and dominant intellectual property portfolio.

Currently, ArmaGen has eight compounds in development. The company’s lead product candidates are AGT-182 for Hunter syndrome, which is expected to enter a Phase 1 clinical trial in the first quarter of 2015, and AGT-181 for Hurler syndrome, which is poised to enter early-stage clinical trials in 2015. We are advancing our pipeline through licensing and collaboration agreements, in-house development efforts, and future partnering opportunities.

ArmaGen was founded in 2004. Our headquarters and research operations are located in Calabasas, CA.

“Our non-invasive approach to delivering therapies to the brain has the potential to revolutionize the treatment of devastating and currently unaddressed neurologic complications of serious diseases.”

James E. Callaway, Ph.D.
Chief Executive Officer
ArmaGen